Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays.

Schwamborn K, Ammann JU, Knüchel R, Hartmann A, Baretton G, Lasitschka F, Schirmacher P, Braunschweig T, Tauber R, Erlmeier F, Hieke-Schulz S, Weichert W.

Virchows Arch. 2019 Jul 2. doi: 10.1007/s00428-019-02610-z. [Epub ahead of print]

PMID:
31267201
2.

Expression of PD-1 and CTLA-4 Are Negative Prognostic Markers in Renal Cell Carcinoma.

Kahlmeyer A, Stöhr CG, Hartmann A, Goebell PJ, Wullich B, Wach S, Taubert H, Erlmeier F.

J Clin Med. 2019 May 24;8(5). pii: E743. doi: 10.3390/jcm8050743.

3.

The Tumor Immune Microenvironment Drives a Prognostic Relevance That Correlates with Bladder Cancer Subtypes.

Pfannstiel C, Strissel PL, Chiappinelli KB, Sikic D, Wach S, Wirtz RM, Wullweber A, Taubert H, Breyer J, Otto W, Worst T, Burger M, Wullich B, Bolenz C, Fuhrich N, Geppert CI, Weyerer V, Stoehr R, Bertz S, Keck B, Erlmeier F, Erben P, Hartmann A, Strick R, Eckstein M; BRIDGE Consortium, Germany; BRIDGE Consortium, Germany; BRIDGE Consortium, Germany; BRIDGE Consortium, Germany.

Cancer Immunol Res. 2019 Jun;7(6):923-938. doi: 10.1158/2326-6066.CIR-18-0758. Epub 2019 Apr 15.

PMID:
30988029
4.

Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab.

Eckstein M, Erben P, Kriegmair MC, Worst TS, Weiß CA, Wirtz RM, Wach S, Stoehr R, Sikic D, Geppert CI, Weyerer V, Bertz S, Breyer J, Otto W, Keck B, Burger M, Taubert H, Weichert W, Wullich B, Bolenz C, Hartmann A, Erlmeier F.

Eur J Cancer. 2019 Jan;106:234-243. doi: 10.1016/j.ejca.2018.11.007. Epub 2018 Dec 5.

PMID:
30528808
5.

Evolution of PD-1 and PD-L1 Gene and Protein Expression in Primary Tumors and Corresponding Liver Metastases of Metastatic Bladder Cancer.

Eckstein M, Sikic D, Strissel PL, Erlmeier F; BRIDGE Consortium Germany.

Eur Urol. 2018 Oct;74(4):527-529. doi: 10.1016/j.eururo.2018.06.028. Epub 2018 Jul 12. No abstract available.

PMID:
30007816
6.

A multicenter round robin test of PD-L1 expression assessment in urothelial bladder cancer by immunohistochemistry and RT-qPCR with emphasis on prognosis prediction after radical cystectomy.

Eckstein M, Wirtz RM, Pfannstil C, Wach S, Stoehr R, Breyer J, Erlmeier F, Günes C, Nitschke K, Weichert W, Otto W, Keck B, Eidt S, Burger M, Taubert H, Wullich B, Bolenz C, Hartmann A, Erben P.

Oncotarget. 2018 Feb 19;9(19):15001-15014. doi: 10.18632/oncotarget.24531. eCollection 2018 Mar 13.

7.

Corrigendum to "Fatal Systemic Vasoconstriction in a Case of Metastatic Small-Intestinal NET".

Stenzel J, Noe S, Holzapfel K, Erlmeier F, Eyer F.

Case Rep Gastrointest Med. 2017;2017:8694296. doi: 10.1155/2017/8694296. Epub 2017 Dec 3.

8.

Comparison of isolation platforms for detection of circulating renal cell carcinoma cells.

Maertens Y, Humberg V, Erlmeier F, Steffens S, Steinestel J, Bögemann M, Schrader AJ, Bernemann C.

Oncotarget. 2017 Sep 23;8(50):87710-87717. doi: 10.18632/oncotarget.21197. eCollection 2017 Oct 20.

9.

Fatal Systemic Vasoconstriction in a Case of Metastatic Small-Intestinal NET.

Stenzel J, Noe S, Holzapfel K, Erlmeier F, Eyer F.

Case Rep Gastrointest Med. 2017;2017:9810194. doi: 10.1155/2017/9810194. Epub 2017 Jul 18. Erratum in: Case Rep Gastrointest Med. 2017;2017:8694296.

10.

[Fetal autopsies : Relic or still a gold standard?]

Andruszkow J, Weichert W, Braunschweig T, Knüchel-Clarke R, Erlmeier F.

Pathologe. 2017 Sep;38(5):438-447. doi: 10.1007/s00292-017-0324-7. German.

PMID:
28741114
11.

[Adult autopsies during the past decade in Germany : Data from two university hospitals].

Erlmeier F, Weichert W, Knüchel R, Andruszkow J.

Pathologe. 2017 Sep;38(5):430-437. doi: 10.1007/s00292-017-0319-4. German.

PMID:
28698908
12.

[Immunotherapy in urothelial carcinoma from a pathologist's perspective].

Erlmeier F, Steffens S, Hartmann A.

Aktuelle Urol. 2017 Aug;48(4):336-339. doi: 10.1055/s-0043-110087. Epub 2017 Jun 14. German.

PMID:
28614852
13.

Prognostic impact of PD-1 and its ligands in renal cell carcinoma.

Erlmeier F, Weichert W, Schrader AJ, Autenrieth M, Hartmann A, Steffens S, Ivanyi P.

Med Oncol. 2017 Jun;34(6):99. doi: 10.1007/s12032-017-0961-y. Epub 2017 Apr 21. Review.

PMID:
28432616
14.

PD-L2: A prognostic marker in chromophobe renal cell carcinoma?

Erlmeier F, Weichert W, Autenrieth M, Wiedemann M, Schrader AJ, Hartmann A, Ivanyi P, Steffens S.

Med Oncol. 2017 May;34(5):71. doi: 10.1007/s12032-017-0926-1. Epub 2017 Mar 28.

PMID:
28353093
15.

c-Met in chromophobe renal cell carcinoma.

Erlmeier F, Ivanyi P, Hartmann A, Autenrieth M, Wiedemann M, Weichert W, Steffens S.

Med Oncol. 2017 Feb;34(2):15. doi: 10.1007/s12032-016-0874-1. Epub 2016 Dec 29.

PMID:
28035577
16.

The Role of PD-L1 Expression and Intratumoral Lymphocytes in Response to Perioperative Chemotherapy for Urothelial Carcinoma.

Erlmeier F, Seitz AK, Hatzichristodoulou G, Stecher L, Retz M, Gschwend JE, Weichert W, Kübler HR, Horn T.

Bladder Cancer. 2016 Oct 27;2(4):425-432. doi: 10.3233/BLC-160067.

17.

[c-MET Oncogene in Renal Cell Carcinomas].

Erlmeier F, Weichert W, Autenrieth M, Ivanyi P, Hartmann A, Steffens S.

Aktuelle Urol. 2016 Dec;47(6):475-479. doi: 10.1055/s-0042-115401. Epub 2016 Dec 22. Review. German.

PMID:
28006830
18.

Influence of the HER receptor ligand system on sensitivity to cetuximab and trastuzumab in gastric cancer cell lines.

Kneissl J, Hartmann A, Pfarr N, Erlmeier F, Lorber T, Keller S, Zwingenberger G, Weichert W, Luber B.

J Cancer Res Clin Oncol. 2017 Apr;143(4):573-600. doi: 10.1007/s00432-016-2308-z. Epub 2016 Dec 8.

19.

PD-1/PD-L1 expression in chromophobe renal cell carcinoma: An immunological exception?

Erlmeier F, Hartmann A, Autenrieth M, Wiedemann M, Ivanyi P, Steffens S, Weichert W.

Med Oncol. 2016 Nov;33(11):120. Epub 2016 Sep 30.

PMID:
27696122
20.

High-mass-resolution MALDI mass spectrometry imaging of metabolites from formalin-fixed paraffin-embedded tissue.

Ly A, Buck A, Balluff B, Sun N, Gorzolka K, Feuchtinger A, Janssen KP, Kuppen PJ, van de Velde CJ, Weirich G, Erlmeier F, Langer R, Aubele M, Zitzelsberger H, McDonnell L, Aichler M, Walch A.

Nat Protoc. 2016 Aug;11(8):1428-43. doi: 10.1038/nprot.2016.081. Epub 2016 Jul 14.

PMID:
27414759
21.

High-resolution MALDI-FT-ICR MS imaging for the analysis of metabolites from formalin-fixed, paraffin-embedded clinical tissue samples.

Buck A, Ly A, Balluff B, Sun N, Gorzolka K, Feuchtinger A, Janssen KP, Kuppen PJ, van de Velde CJ, Weirich G, Erlmeier F, Langer R, Aubele M, Zitzelsberger H, Aichler M, Walch A.

J Pathol. 2015 Sep;237(1):123-32. doi: 10.1002/path.4560. Epub 2015 Jun 30.

PMID:
25965788
22.

Supremacy of modern morphometry in typing renal oncocytoma and malignant look-alikes.

Erlmeier F, Feuchtinger A, Borgmann D, Rudelius M, Autenrieth M, Walch AK, Weirich G.

Histochem Cell Biol. 2015 Aug;144(2):147-56. doi: 10.1007/s00418-015-1324-4. Epub 2015 May 1.

PMID:
25929744

Supplemental Content

Loading ...
Support Center